Skip to content
10-K

Annual Report

Artiva Biotherapeutics, Inc. ARTV

0001193125-26-100135

← back to feed
Filed
Mar 10, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 24.44M sh
Shares Diluted FY 2025 · Dec 31, 2024 11.26M sh
Capex FY 2025 · Dec 31, 2025 $2.59M
Capex FY 2025 · Dec 31, 2024 $642K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$76.75M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$55.03M
Short Term Investments FY 2025 · Dec 31, 2025 $81.31M
Short Term Investments FY 2025 · Dec 31, 2024 $145.19M
Cash And Equivalents FY 2025 · Dec 31, 2025 $26.7M
Cash And Equivalents FY 2025 · Dec 31, 2024 $40.24M
Stockholders Equity FY 2025 · Dec 31, 2025 $109.97M
Stockholders Equity FY 2025 · Dec 31, 2024 $186.64M
Stockholders Equity FY 2025 · Dec 31, 2023 −$162.02M
Current Liabilities FY 2025 · Dec 31, 2025 $13.09M
Current Liabilities FY 2025 · Dec 31, 2024 $12.25M
Total Liabilities FY 2025 · Dec 31, 2025 $20.97M
Total Liabilities FY 2025 · Dec 31, 2024 $22.94M
Current Assets FY 2025 · Dec 31, 2025 $112.67M
Current Assets FY 2025 · Dec 31, 2024 $188.63M
Total Assets FY 2025 · Dec 31, 2025 $130.94M
Total Assets FY 2025 · Dec 31, 2024 $209.58M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.43
Eps Diluted FY 2025 · Dec 31, 2024 −$5.81
Eps Basic FY 2025 · Dec 31, 2025 −$3.43
Eps Basic FY 2025 · Dec 31, 2024 −$5.81
Sga Expense FY 2025 · Dec 31, 2025 $20.27M
Sga Expense FY 2025 · Dec 31, 2024 $17.21M
Rd Expense FY 2025 · Dec 31, 2025 $69.54M
Rd Expense FY 2025 · Dec 31, 2024 $50.33M
Net Income FY 2025 · Dec 31, 2025 −$83.87M
Net Income FY 2025 · Dec 31, 2024 −$65.37M
Operating Income FY 2025 · Dec 31, 2025 −$89.81M
Operating Income FY 2025 · Dec 31, 2024 −$67.28M